163
Participants
Start Date
March 29, 2022
Primary Completion Date
September 30, 2025
Study Completion Date
December 31, 2025
zatolmilast
Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo
Placebo
Placebo
Icahn School of Medicine at Mount Sinai Hospital, New York
Clinic for Special Children, Strasburg
Suburban Research Associates, Media
Kennedy Krieger Institute, Baltimore
Greenwood Genetic Center, Greenville
Emory University School of Medicine, Atlanta
University of Miami, Miami
Cincinatti Children's Hospital Medical Center, Cincinnati
Rush University Medical Center, Chicago
University of Kansas Medical Center, Kansas City
Children's Hospital Colorado, Aurora
University of Utah and Primary Childrens Hospital, Salt Lake City
Amnova Clinical Research, Irvine
Thompson Autism & Neurodevelopment Center - CHOC, Orange
UC Davis, Sacramento
Boston Children's Hospital, Boston
U Mass, Worcester
Lead Sponsor
Tetra Discovery Partners
INDUSTRY